This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moderna (MRNA) Set to Join S&P 500 Riding on Vaccine Success
by Zacks Equity Research
Moderna's (MRNA) success with its COVID-19 vaccine, mRNA-1273, continues to drive the stock. The company crosses $100-billion in market capitalization and will join the S&P 500 soon.
Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall
by Kinjel Shah
Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
by Zacks Equity Research
The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.
Moderna (MRNA) Set to Supply Argentina With COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) signs an agreement with the government of Argentina for supplying 20 million doses of its COVID-19 vaccine, mRNA-1273, or an updated booster vaccine shot, if approved.
J&J (JNJ) COVID-19 Jab Linked to New Rare Neurological Disorder
by Zacks Equity Research
FDA warns of increased risk of Guillain-Barre syndrome, a rare neurological disorder with J&J's (JNJ) COVID-19 vaccine.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $39.76 in the latest trading session, marking a +0.38% move from the prior day.
Bear of the Day: Inovio Pharmaceuticals (INO)
by Madeleine Johnson
Is it too late to buy this coronavirus vaccine stock?
Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H
by Zacks Equity Research
Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.
BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster
by Zacks Equity Research
BioNTech (BNTX) and partner Pfizer plan to get authorization for COVID-19 booster vaccine shot in the United States owing the emerging Delta variant of the virus.
Vaccine Stocks Fall as Delta Becomes Dominant Variant in US
by Kinjel Shah
Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More
by Zacks Equity Research
The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).
Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer
by Zacks Equity Research
Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.
Company News for Jul 7, 2021
by Zacks Equity Research
Companies In The News Are: AMZN, MSFT, PFE, AMC, OCGN.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $39.73, moving +0.43% from the previous trading session.
Moderna ETFs to Rise on Positive COVID-19 Vaccine Updates
by Sweta Jaiswal, FRM
Moderna has once again come up with interesting updates about its COVID-19 vaccine.
How Potent Are JNJ & Other COVID-19 Jabs Against Delta Variant?
by Kinjel Shah
All available vaccines are mostly more effective against the Delta variant after two doses, and less effective after the first dose.
Pharma Stock Roundup: EU Nod to RHHBY, MRK Drugs, FDA and Pipeline Updates
by Kinjel Shah
EU approves Roche's (RHHBY) Enspryng and Merck's (MRK) Keytruda for a new indication. FDA grants EUA to Roche's Actemra for COVID-19.
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, BioNTech and Bayer
CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study
by Zacks Equity Research
CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.
Deciphera (DCPH) Begins Dosing in Study on Cancer Candidate
by Zacks Equity Research
Deciphera (DCPH) doses the first patient in a phase I study evaluating its ULK kinase inhibitor, DCC-3116, for treating advanced/metastatic tumors driven by mutations in RAS/RAF genes.
3 Big Drugmakers Likely to be in Focus in Second Half of 2021
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.
The Zacks Analyst Blog Highlights: Pfizer, Qualcomm, Philip Morris International, Freeport-McMoRan and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Qualcomm, Philip Morris International, Freeport-McMoRan and FedEx
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU (Revised)
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study
Top Stock Reports for Pfizer, Qualcomm & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), QUALCOMM (QCOM), and Philip Morris International (PM).